Assessing the association of psoriasis on mental health outcomes in the United States utilizing the 2023 National Health Interview Survey

Psoriasis (PsO) has been associated with a range of psychiatric disorders, yet the availability of national-level data remains limited and outdated. This study utilzied the 2023 National Health Interview Survey recent data to elucidate the psychological impact of PsO. This cross-sectional study compared participants with self-reported PsO to those without using Wilcoxon rank sum and chi-square tests. Adjusted logistic regression models assessed odds for life satisfaction, depression, anxiety, and use of medication/therapy for mental health reasons. Weighted analysis demonstrated 7,424,788 participants with self-reported PsO of which 51% were men and 79% identified as White (79%). Compared to those without PsO, those with PsO had higher odds of reporting dissatisfaction with life (OR = 2.07 95% CI: 1.52–2.83, p < 0.001), anxiety (OR = 2.06, 95% CI: 1.68–2.53, p < 0.001), depression (OR = 1.80, 95% CI: 1.52–2.14, p < 0.001) and use of mental health therapy or medication (OR = 1.76, 95% CI: 1.42–2.18, p < 0.001). Our national analysis shows that PsO is associated with a significant mental health burden doubling the odds for anxiety and life dissatisfaction and increasing the likelihood for depression and mental health treatment use.